An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis

被引:17
作者
Kutwin, Magdalena [1 ]
Migdalska-Sek, Monika [2 ]
Brzezianska-Lasota, Ewa [2 ]
Zelga, Piotr [3 ]
Wozniacka, Anna [1 ]
机构
[1] Med Univ Lodz, Dept Dermatol & Venereol, PL-90647 Lodz, Poland
[2] Med Univ Lodz, Dept Biomed & Genet, PL-92213 Lodz, Poland
[3] Univ Cambridge, Dept Surg, Cambridge CB2 0QQ, England
关键词
cytokines; disease activity; immunology; molecular markers; psoriasis; skin disease; T-HELPER TYPE-1; IFN-GAMMA; PLAQUE PSORIASIS; DOUBLE-BLIND; INTERLEUKIN-10; EXPRESSION; EPIDERMAL HYPERPLASIA; AUTOIMMUNE DISORDERS; CYTOKINE PROFILE; DENDRITIC CELLS; HUMAN MONOCYTES;
D O I
10.3390/jcm10245834
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Being one of the most common dermatological inflammatory disorders, psoriasis is a frequent subject of research. It is considered to be a T cell-dependent immune disease whose pathogenesis is influenced by cytokines, such as IL-10, IL-17A, IL-17RA, IL-23A and IL-23R. The present study examines whether the expression of selected genes is correlated with the clinical course of psoriasis, assessed by the PASI, BSA and DLQI scales. Skin biopsies and blood from 60 patients with psoriasis and 24 healthy controls were obtained for RNA isolation. These were subjected to RT-PCR for IL-10, IL-17A, IL-17RA, IL-23A and IL-23R genes. The results were presented as an RQ value. IL-17A and IL-23R expression levels were higher in psoriatic skin compared to controls, while IL-10 expression was lower. A positive correlation was also found between RQ for IL-23A and PASI index. Psoriatic skin is characterised by elevated expression of IL-17A and IL-23R and decreased expression of IL-10. This indicates that the selected cytokines may be one of the factors involved in the pathogenesis and pathomechanism of psoriasis, but more studies need to be made before we can elucidate the exact reason for the unbalance in cytokine expression levels.
引用
收藏
页数:17
相关论文
共 122 条
[1]   RETRACTED: The role of gut microbiome in the pathogenesis of psoriasis and the therapeutic effects of probiotics (Retracted Article) [J].
Alesa, Dalal, I ;
Alshamrani, Haidar M. ;
Alzahrani, Yahya A. ;
Alamssi, Dania N. ;
Alzahrani, Nada S. ;
Almohammadi, Marwan E. .
JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2019, 8 (11) :3496-3503
[2]   Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature [J].
Almutairi, Nawaf ;
Eassa, Bayoumy .
POSTEPY DERMATOLOGII I ALERGOLOGII, 2021, 38 (02) :281-288
[3]   Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity [J].
Arican, O ;
Aral, M ;
Sasmaz, S ;
Ciragil, P .
MEDIATORS OF INFLAMMATION, 2005, (05) :273-279
[4]   Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review [J].
Armstrong, April W. ;
Read, Charlotte .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (19) :1945-1960
[5]   The treatment of psoriasis with IL-10:: rationale and review of the first clinical trials [J].
Asadullah, K ;
Döcke, WD ;
Sabat, R ;
Volk, HD ;
Sterry, W .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (01) :95-102
[6]   IL-10 is a key cytokine in psoriasis -: Proof of principle by IL-10 therapy:: A new therapeutic approach [J].
Asadullah, K ;
Sterry, W ;
Stephanek, K ;
Jasulaitis, D ;
Leupold, M ;
Audring, H ;
Volk, HD ;
Döcke, WD .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :783-794
[7]   Interleukin 10 treatment of psoriasis -: Clinical results of a phase 2 trial [J].
Asadullah, K ;
Döcke, WD ;
Ebeling, M ;
Friedrich, M ;
Belbe, G ;
Audring, H ;
Volk, HD ;
Sterry, W .
ARCHIVES OF DERMATOLOGY, 1999, 135 (02) :187-192
[8]  
Asadullah K., 2000, MADAME CURIE BIOSCIE
[9]   Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5years of treatment (SCULPTURE Extension Study) [J].
Bissonnette, R. ;
Luger, T. ;
Thaci, D. ;
Toth, D. ;
Lacombe, A. ;
Xia, S. ;
Mazur, R. ;
Patekar, M. ;
Charef, P. ;
Milutinovic, M. ;
Leonardi, C. ;
Mrowietz, U. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (09) :1507-1514
[10]   Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study [J].
Blauvelt, Andrew ;
Papp, Kim A. ;
Merola, Joseph F. ;
Gottlieb, Alice B. ;
Cross, Nancy ;
Madden, Cynthia ;
Wang, Maggie ;
Cioffi, Christopher ;
Griffiths, Christopher E. M. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) :1367-1374